Advertisement

Study Meets Primary Endpoint by Significantly Improving Bone Metastasis-Free Survival for More Than Four Months

Up to 90 Percent of Men with Advanced Prostate Cancer Will Develop Bone Metastases

THOUSAND OAKS, Calif., May 17, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) today announced primary results of a pivotal Phase 3 trial (’147) demonstrating that XGEVA™ (denosumab) significantly increased bone metastasis-free survival for more than four months in men with castrate-resistant metastatic prostate cancer that has not yet spread to bone.  Full results of the ‘147 study were presented for the first time today in a late-breaking plenary session at the American Urological Association (AUA) 2011 Annual Meeting in Washington, D.C.

Read the rest of this entry

SOURCE

Advertisement
Advertisement